Hepatoprotective effect of Omega-3 PUFAs against acute paracetamol-induced hepatic injury confirmed by FTIR.


Journal

Human & experimental toxicology
ISSN: 1477-0903
Titre abrégé: Hum Exp Toxicol
Pays: England
ID NLM: 9004560

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 11 9 2020
medline: 25 2 2023
entrez: 10 9 2020
Statut: ppublish

Résumé

Acute paracetamol over dose-induced hepatotoxicity is considered an important medical hazard especially among women. Omega-3 long-chain polyunsaturated fatty acids (Omega-3 PUFAs) daily doses are nowadays recommended for their antioxidant and anti-inflammatory potentials. Fourier transform infrared (FTIR) spectroscopy is considered a reliable method in analyzing cellular alterations and is now efficiently used to diagnose several diseases and the efficacy of drugs even in the early stages. The aim of our study was to evaluate the hepatoprotective effect of Omega-3 PUFAs against paracetamol-induced hepatotoxicity in rats confirmed through measuring protein alterations in hepatocytes by FTIR. Rats were pretreated with Omega-3 PUFAs (50 and 100 mg/kg) for 21 days prior to oral ingestion of paracetamol. FTIR results revealed that Omega-3 PUFAs (50 mg/kg) limited the toxic effects of paracetamol by restoring the hepatic amide I to amide II ratio. In addition; biochemical analyses demonstrated that serum ALT, AST, Cholesterol, LDL-cholesterol and Il-6 levels as well as hepatic TNF-α, MDA, NOx levels were decreased. Besides; serum HDL-cholesterol level and hepatic GSH level were increased. Histopathological examinations of hepatic sections validated the hepatoprotective potential. The overall effect of this dose was comparable to those of the usual recommended hepatoprotective supplement; silymarin. In conclusion; it would be recommended to use Omega-3 PUFAs in low doses on daily bases as a hepatoprotective agent.

Identifiants

pubmed: 32909844
doi: 10.1177/0960327120954522
doi:

Substances chimiques

Analgesics, Non-Narcotic 0
Fatty Acids, Omega-3 0
Il6 protein, rat 0
Interleukin-6 0
Protective Agents 0
Tumor Necrosis Factor-alpha 0
Nitric Oxide 31C4KY9ESH
Acetaminophen 362O9ITL9D
Malondialdehyde 4Y8F71G49Q
Cholesterol 97C5T2UQ7J
Aspartate Aminotransferases EC 2.6.1.1
Alanine Transaminase EC 2.6.1.2
Glutathione GAN16C9B8O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

526-537

Auteurs

Zeinab A El-Gendy (ZA)

Department of Pharmacology, Medical Research Division, 68787National Research Centre, Dokki, Giza, Egypt.

Seham A El-Batran (SA)

Department of Pharmacology, Medical Research Division, 68787National Research Centre, Dokki, Giza, Egypt.

Sah Youssef (S)

Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.

A Ramadan (A)

Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.

Walid El Hotaby (WE)

Department of Spectroscopy, Physics Division, 68787National Research Centre, Dokki, Giza, Egypt.

Rofanda M Bakeer (RM)

Department of Pathology, Faculty of Medicine, Helwan University, Helwan, Egypt.
Department of Pathology, 110123October University of Modern Sciences and Arts (MSA) University, Egypt.

Rania F Ahmed (RF)

Department of Pharmacology, Medical Research Division, 68787National Research Centre, Dokki, Giza, Egypt.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH